Twist Bioscience Reports Record Revenue and Raises Guidance for Fiscal 2024

Details

The company also raised its full-year revenue guidance to between $288 million and $293 million, with an expected gross margin of 40% to 41%. Additionally, Twist Bioscience expanded its Express Genes service to all prep scales and appointed Adam Laponis as its new Chief Financial Officer.

Items reported

Exhibits (1)

About Twist Bioscience Corporation

Twist Bioscience Corporation is a pioneering biotechnology firm revolutionizing the field of synthetic DNA. The company's primary function is to produce synthetic DNA using a proprietary silicon-based manufacturing platform, enabling the creation of high-quality, accurate, and cost-effective DNA at scale. Twist Bioscience's innovations impact multiple sectors, including pharmaceuticals, industrial chemicals, agriculture, and data storage, offering transformative solutions in drug development, crop protection, and genomic research. By leveraging its proprietary DNA synthesis platform, Twist Bioscience plays a vital role in the broader biotechnology market, facilitating advancements that drive progress in personalized medicine and sustainable practices. With its cutting-edge technology, the company provides researchers and businesses with access to a wide array of DNA products and solutions essential for scientific discovery and technological innovation, underpinning its significance in the expanding biotech landscape.